Limitations of quantiferon-TB gold assay for screening of psoriasis patients prior to anti-tumour necrotic factor treatment

Infect Dis (Lond). 2018 Apr;50(4):317-319. doi: 10.1080/23744235.2017.1395068. Epub 2017 Oct 26.

Authors

Alessandra Bua¹, Stefania Zanetti¹, Maria Francesca Peigottu², Maria Antonetta Montesu², Paola Molicotti¹

Affiliations

¹ a Department of Biomedical Sciences, Section of Experimental and Clinical Microbiology , University of Sassari , Sassari , Italy.
² b Dermatology Unit, Department of Surgical, Microsurgical and Medical Sciences , University of Sassari , Sassari , Italy.

PMID: 29069962
DOI: 10.1080/23744235.2017.1395068

No abstract available

Publication types

Letter
Kommentar

MeSH terms

Humans
Interferon-gamma
Interferon-gamma Release Tests
Latent Tuberculosis
Mass Screening
Neoplasms
Psoriasis*
Tuberculin Test
Tuberculosis
Tumor Necrosis Factor-alpha*

Substances

Tumor Necrosis Factor-alpha
Interferon-gamma